Related Experiment Videos
Coagulation inhibitor substitution during sepsis
F Fourrier1, M Jourdain, A Tournois
1Service de Réanimation Polyvalente, Hôpital B, CHRU, Lille, France.
Intensive Care Medicine
|November 1, 1995
Summary
Coagulation inhibitors like C1-inhibitor (C1-Inh.) show promise for sepsis treatment, improving hypotension. Antithrombin III (AT III) and protein C substitution require further study for efficacy in human sepsis.
Area of Science:
- Coagulation and complement system interactions in sepsis.
- Pharmacological modulation of sepsis-induced coagulopathy.
Background:
- Sepsis triggers complex coagulation and complement system activation.
- Deficiencies in natural coagulation inhibitors like C1-inhibitor (C1-Inh.) are observed in septic patients.
- Sepsis-induced disseminated intravascular coagulation (DIC) involves tissue factor (TF) activation.
Purpose of the Study:
- To review the rationale and results of using coagulation inhibitors in sepsis.
- To evaluate the potential of C1-Inh., antithrombin III (AT III), and protein C substitution therapies.
Main Methods:
- Review of experimental and human sepsis studies.
- Analysis of physiological inhibition mechanisms by C1-Inh., AT III, and protein C-protein S system.
- Evaluation of substitution strategies for these inhibitors.
Main Results:
- C1-Inh. substitution in humans is safe with preliminary positive effects on septic shock.
- AT III concentrate prevented DIC and death in animal models, but human studies show debated efficacy and no mortality reduction.
- Protein C activity is reduced in sepsis, and protein S is inhibited; activated protein C and protein S protect animals.
Conclusions:
- C1-Inh. substitution may benefit septic shock patients.
- The clinical utility of AT III substitution in human sepsis remains uncertain.
- Further research is needed on combining different coagulation inhibitors for sepsis treatment.